Sorafenib: Recent update on activity as a single agent and in combination with interferon-α2 in patients with advanced-stage renal cell carcinoma

Clinical Genitourinary Cancer

Volumn 4, Issue 4, 2006, Pages 246-248

  Reddy, G Kesava ^a   Bukowski, Ronald M ^b  

^a CIG Media Group   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Combination therapy; Efficacy; Growth factors; Progression free survival; Toxicity

Indexed keywords

FLT3 LIGAND; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RAF PROTEIN; RECOMBINANT ALPHA2 INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; SORAFENIB; STEM CELL FACTOR RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADVANCED CANCER; ANOREXIA; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DRUG APPROVAL; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FATIGUE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOPHOSPHATEMIA; KIDNEY CARCINOMA; LEUKOPENIA; LYMPHOCYTOPENIA; MAXIMUM TOLERATED DOSE; METABOLIC DISORDER; NEUTROPENIA; OVERALL SURVIVAL; RASH; SHORT SURVEY; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 33646867029     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2006.n.002     Document Type: Review

References (7)

1. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64:7099-7109.
2. Ahmad T, Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res 2004; 10:63885-63925.
3. Clark JW, Eder JP, Ryan D, et al. Safety and pharmacokinetics of the dual action raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005; 11:5472-5480.
4. Escudier B, Szczylik C, Eisen T, et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY43-9006) in patients with advanced metastatic renal cell carcinoma. J Clin Oncol 2005; 23(16 suppl):380s (Abstract #LBA4510).
5. Escudier B, Szczylik C, Eisen T, et al. Randomized phase III trial of the multi-kinase inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Eur J Cancer Suppl 2005; 3:226 (Abstract #794).
6. Gollob JA, Moran K, Richmond T, et al. Phase II trial of sorafenib (BAY 43-9006) in combination with interferon alpha 2b in patients with metastatic renal cell carcinoma. Eur J Cancer Suppl 2005; 3:226 (Abstract #795).
7. Robert C, Lassau N, Angevin E, et al. Phase I trial of sorafenib (BAY 43-9006) in combination with interferon alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma and malignant melanoma. Eur J Cancer Suppl 2005; 3:226 (Abstract #883).